Advanced Medical Optics (EYE)

PART I

Advanced Medical Optics, Inc. (“AMO” or the “Company”) was incorporated in Delaware in October 2001 as a subsidiary of Allergan, Inc. (“Allergan”). Allergan spun-off our company to its stockholders by way of a distribution of all of our shares of common stock on June 29, 2002. As a result of our spin-off from Allergan, we are an independent public company, and Allergan has no continuing stock ownership in us. Unless the context requires otherwise, references to “AMO,” the “Company,” “we,” “us” or “our” refer to Advanced Medical Optics, Inc. and its subsidiaries.

PART I

PART I

PART II

Dividends. We have never declared or paid any cash dividends on our common stock or any of our securities. We do not expect to pay cash dividends on our capital stock in the foreseeable future. We intend to retain our future earnings to continue to fund the development and growth of our business as well as repay long-term debt. In addition, our amended and restated Credit Facility prohibits us from paying cash dividends.

Market Information. The following table shows the quarterly closing price range of our common stock during the periods listed.

Our common stock is listed on the New York Stock Exchange and is traded under the symbol “EYE.” The closing price of our common stock was $21.92 on February 11, 2009.

The approximate number of stockholders of record was 4,538 as of February 11, 2009.

31

Table of Contents

The following sets forth shares purchased from employees to pay taxes related to our equity incentive plan:

PART II

PART II

PART IV

All other schedules have been omitted for the reason that the required information is presented in financial statements or notes thereto, the amounts involved are not significant or the schedules are not applicable.

Reference is made to the Index of Exhibits beginning at page S-3 of this report.

There are no financial statements required to be filed by Regulation S-X which are excluded from this report by Rule 14 a-3(b)(1).

153

Table of Contents

PART IV

PART IV

PART IV

All other schedules have been omitted for the reason that the required information is presented in financial statements or notes thereto, the amounts involved are not significant or the schedules are not applicable.

Reference is made to the Index of Exhibits beginning at page S-3 of this report.

There are no financial statements required to be filed by Regulation S-X which are excluded from this report by Rule 14 a-3(b)(1).

98

Table of Contents

PART IV

All other schedules have been omitted for the reason that the required information is presented in
financial statements or notes thereto, the amounts involved are not significant or the schedules are not applicable.

Reference is made to the Index of
Exhibits beginning at page S-3 of this report.

There are no financial
statements required to be filed by Regulation S-X which are excluded from this report by Rule 14 a-3(b)(1).

98

Table of Contents

Item 15. Exhibits, Financial Statement Schedules

(a)                                  Index to Financial Statements 

All other schedules have been omitted for the reason that the required information is presented in financial statements or notes thereto, the amounts involved are not significant or the schedules are not applicable.

(b)                                 Item 601 Exhibits

Reference is made to the Index of Exhibits beginning at page S-3 of this report.

(c)                                  Other Financial Statements

There are no financial statements required to be filed by Regulation S-X which are excluded from this report by Rule 14 a-3(b)(1).

91

Item 10. Directors and Executive Officers of Advanced Medical Optics, Inc.

Information required by this item, including that required pursuant to Item 401 of Regulation S-K, is included under the headings “Election of Directors” and “Executive Officers” in our proxy statement for the 2006 annual meeting of stockholders (the “Proxy Statement”), which will be filed no later than 120 days after the close of our fiscal year ended December 31, 2005 and which is incorporated herein by reference.

The information required by Item 405 of Regulation S-K is included in the Proxy Statement under the section entitled “Section 16(a) Beneficial Ownership Reporting Compliance” and is incorporated herein by reference.

Item 11. Executive Compensation

The sections entitled “Certain Relationships and Related Transactions,” “Executive Compensation,” and “Comparison of Cumulative Total Return,” and the subsection entitled “Director Compensation” included in the Proxy Statement are incorporated herein by reference.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The common stock information in the section entitled “Ownership of Our Stock” in the Proxy Statement is incorporated herein by reference. The information regarding securities authorized for issuance under equity compensation plans in the subsection of our Proxy Statement entitled “Equity Compensation Plans Approved by Stockholders” is incorporated herein by reference.

Item 13. Certain Relationships and Related Transactions

The section entitled “Certain Relationships and Related Transactions” in the Proxy Statement is incorporated herein by reference.

Item 14. Principal Accountant Fees and Services

The section entitled “Independent Registered Public Accounting Firm” in the Proxy Statement is incorporated herein by reference.

86